Oruka Therapeutics (ORKA) Stock Forecast: StockMap's 2-Week Call
ORKA stock forecast: StockMap's model leans Outperform on Oruka Therapeutics for the two weeks after the Nov 19 close, toward ORKA doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.
Oruka Therapeutics last closed at $97.57, +1.91% on the session.
Against the IVW growth benchmark the position is +4.24% over the forecast window.
Oruka Therapeutics' market cap is $6.62B as of November 19, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 24 (too close to call).
Where ORKA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 10 bullish and 5 bearish.
Agreement across those insights is 67%.
8 daily calls for ORKA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Oruka Therapeutics in the 27th percentile on return on equity, where 100 is best.
Oruka Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Oruka Therapeutics as the 41st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Oruka Therapeutics ranks 12th of 394 in the group, against a group median of -0.27.